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Abstract
BACKGROUND: The reliable method for determination of 
identity and radiochemical purity (RCP) is of great importance 
in radiopharmaceutical development. This is especially relevant 
when more than one form of radiometal/ligand complex can be 
formed during radiolabelling, such as complexes of 99mTc or 188Re 
with meso-2,3-dimercaptosuccinic acid (DMSA), where depend-
ing on the pH, metal can occur either at +3 or +5 oxidation state. 
The aim of our study was to evaluate possibilities for optimiza-
tion of chromatographic systems leading to specific and reliable 
analytical method for determination of the identity and RCP of 
DMSA complexes with 99mTc or 188Re. 
MATERIAL AND METHODS: The commercial DMSA kits 
(POLATOM) were used for preparation of technetium-99m 
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(III) and (V) complexes with DMSA. 99mTc(V)-DMSA complexes 
were prepared by addition of NaHCO3 to the kit vial prior to 
99mTc-eluate to obtain pH ~8. 188Re(V)-DMSA was prepared either 
directly or using intermediate 188Re(III)-EDTA complex added 
to DMSA. RCP was evaluated by TLC using: ITLC-SG deve-
loped in methylethylketon, SG60 coated plates developed in: 
n-BuOH/H2O/CH3COOH and n-PrOH/H2O/CH3COOH systems, 
and in H2O. Comparative biodistribution studies were performed 
in normal Wistar rats.
RESULTS: Using silica gel plates and n-PrOH, H2O and acetic 
acid in the developing solution, we observed that 99mTc/188Re(III)-
DMSA and 99mTc/188Re(V)-DMSA complexes could be well 
separated from each other and from the impurities in the form 
of free pertechnetate/perrhenate. In vivo studies showed quite 
different biodistribution of 99mTc(III)- and 99mTc(V)-DMSA. The 
trivalent complex accumulated mainly in kidneys (>40%ID), 
while 99mTc(V)-DMSA revealed high excretion with urine and 
relatively high concentration in osseous tissue (ca. 2 %ID/g). 
Accumulation of this complex in kidneys was very low (ca. 
2.5 %ID). Biodistribution pattern of 188Re(V)-DMSA prepared 
directly was almost identical to that of 99mTc(V)-DMSA. Biodistri-
bution results of the 188Re preparation obtained using 188Re(III)-
EDTA intermediate indicated that the preparation contained the 
mixture of penta- and trivalent 188Re complexes. The quite high 
accumulation of radioactivity in kidneys (23 %ID) gave evidence 
of the presence of 188Re(III)-DMSA in this preparation, what was 
also confirmed by the results of TLC analysis performed using 
silica gel plate and n-propanol/water/acetic acid as developing 
system. 
CONCLUSIONS: Based on our study, we have made recom-
mendation on the suitable methods for investigations of RCP of 
DMSA complexes, i.e.: SG60 plates developed in the mixture 
of n-propanol/water/acetic acid, which enable determination 
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of the tri- and pentavalent DMSA complexes, as well as, the 
pertechnetate/perrhenate impurity, and developed in water for 
determination of the colloidal residue. 
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Background
Meso-2,3-dimercaptosuccinic acid (DMSA, succimer) 
is a water-soluble, organosulfur compound used for preparation 
of radiopharmaceuticals of great importance for nuclear medicine 
applications. Trivalent technetium-99m dimercaptosuccinic acid, 
99mTc(III)-DMSA, is a widely used renal imaging agent. Pentavalent 
99mTc-dimercaptosuccinic acid, 99mTc(V)-DMSA, is used for imaging 
of medullary and insular carcinoma of the thyroid [1–3], for some 
other soft tissue tumours [4–9], and skeletal metastases from 
breast carcinoma [10, 11]. 186/188Re(V)-DMSA is a radiotherapeu-
tic analogue of 99mTc(V)-DMSA, and its use is well established in 
a variety of histologically different tumours and especially in bone 
metastases arising from breast and prostate carcinomas [12–14].
The reliable method for determination of identity and radio-
chemical purity (RCP) is of great importance in radiopharmaceu-
tical development. This is especially relevant when more than 
one form of radiometal/ligand complex can be formed during 
radiolabelling, and 99mTc or 188Re complexes with DMSA present 
such a case. Under a wide range of pH several different entities of 
radiolabelled DMSA can be formed with quite different biological 
behaviour. In DMSA complexes with 99mTc, depending on pH, the 
metal can occur at +3 or +5 oxidation state. Preliminary structural 
analysis by NMR [15] suggests that in acidic media (pH around 3), 
a hexacoordinated asymmetric bis-complex is formed in which 
one molecule is bound to technetium via two -S- bridges and one 
-O- bridge, while the other is bound via one -S- bridge and two 
-O- bridges, and one –SH remains free (Figure 1). In an alkaline 
medium (pH ≥ 8), all of the free –SH groups of dimercaptosuccinic 
acid (DMSA) are available, forming a pentacoordinated bis-com-
plex with the metal central ion coordinated by four thiolates of two 
DMSA ligands and an apical oxo group. 99mTc(V)-DMSA, as well 
as 188Re(V)-DMSA, are in fact a mixture of three stereoisomers aris-
ing from different orientations of the 4 carboxylate groups of the 
complex [TcO(DMSA)2]
-1 (Figure 2).
Although there is the monograph No. 0643 in the European 
Pharmacopoeia [16] describing RCP test for 99mTc-succimer 
(99mTc(III)-DMSA) using ITLC SG plate and methylethylketone 
as mobile phase, this method is not specific to distinct possible 
forms of the complex and allows only the determination of free 
99mTc-pertechnetate. Under these chromatographic conditions both 
99mTc(III)-DMSA and 99mTc(V)-DMSA are retained at the origin, the 
same as colloidal residues of 99mTc, and only 99mTc-pertechnetate 
moves with the solvent. Although this kind of information may 
be considered sufficient for routine quality control purposes of 
radiopharmaceutical obtained from a commercially prepared 
kit with marketing authorization, its practical utility for testing 
99mTc(V)-DMSA preparations is hardly acceptable. Up to date, 
biodistribution studies have been involved to confirm potential 
clinical efficacy of the radioactive DMSA preparations. However, in 
order to reduce the number of experiments in laboratory animals, 
routine biodistribution testing should be replaced by other suit-
able physico-chemical or in vitro methods. Development of such 
methods for comprehensive investigation of the radioactive DMSA 
complexes is still needed. 
The aim of this work was to evaluate the currently available 
chromatographic systems and their optimization in order to provide 
specific and reliable analytical methods for investigation of DMSA 
complexes with 99mTc or 188Re. 
Material and methods
Chemicals 
The kit for preparation of technetium-99m succimer injection 
(99mTc-DMSA MTcK-12, NCNR RC POLATOM, Poland) was used for 
preparation of technetium-99m (III) and (V) complexes with DMSA.
For 188Re(V)-DMSA preparation two preformulated kits were 
developed:
Kit 1 for direct preparation of 188Re(V)-DMSA consisting of two vials:
 — vial 1-1: 2 mg DMSA and 1 mL of 0.05 M carbonate buffer of 
pH 9.0 (freeze-dried);
Figure 1. Suggested structure of bisDMSA complex with trivalent 99mTc
Figure 2. Stereoisomers of pentavalent 99mTc (188Re) complex with DMSA
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 — vial 1-2: 2 mL solution of stannous chloride in 1 M HCl 
(2.0 mg/mL).
Kit 2 for indirect radiolabelling:
 — vial 2-1: 5.0 mg EDTA, 5.0 mg mannitol and 1.0 mg stan-
nous chloride (freeze-dried);
 — vial 2-2: 0.5 mg DMSA in 1 mL of 0.1 M phosphate buffer of 
pH 7.4 (freeze-dried);
 — vial 2-3: 1 mL solution of 0.1 M HCl.
The eluate of sodium pertechnetate (99mTc) was obtained 
from Technetium (99mTc) Generator POLGENTEC and the eluate 
of sodium perrhenate (188Re) was obtained from 188W/188Re gene-
rator [17] (both radionuclide generators produced by NCNR RC 
POLATOM, Poland). 
All other chemicals and materials were used as supplied and 
were of analytical or HPLC grade unless otherwise stated.
Preparation of DMSA complexes
99mTc(III)-DMSA was prepared following manufacturer’s instruc-
tion for 99mTc-labelling. For preparation of 99mTc(V)-DMSA com-
plexes, 0.18 mL of 7% NaHCO3 was added to the commercial 
DMSA kit vial to obtain pH ~8, followed by 4.82 mL of the eluate 
of sodium pertechnetate (99mTc) [18]. 
188Re(V)-DMSA preparations were obtained either by the 
direct labelling method [19] or using the pre-formed complex of 
188Re-EDTA, which was added to DMSA at pH 7.4 [20]. For both 
methods, kits formulations were prepared (Kit 1 and Kit 2) as de-
scribed in paragraph on Chemicals. 
Radiolabelling of DMSA with 188Re: 
 — using Kit 1: 1 mL of 188ReO4
- eluate was added to the 1-1 vial, 
followed by 1 mL solution (2.0 mg/mL) of stannous chloride in 1 
M HCl (vial 1-2). The mixture was incubated for 30 min at 95 oC. 
 — using Kit 2: 188Re(III)-EDTA precursor was prepared by adding 
3-5 mL of 188ReO4
- eluate to the 2-1 vial followed by 0.5 mL of 
0.1 M HCl solution from the vial 2-3. The mixture was incubated 
for 20-30 min at room temperature. Then, 1 mL of such ob-
tained solution was transferred to the 2-2 vial and the content 
was incubated for 10 min at RT.
Radioanalytical methods
Several chromatographic systems were tested: 
 — European Pharmacopoeia method [16].
 — ITLC-SG (P/N 61886, PALL) strips and methylethylketone 
(MEK) as mobile phase. 
 — TLC on silica gel plates as proposed by Westera et al. [21]:
 silica gel TLC plates (Kieselgel 60 DC-Plastikfolien; 105748; 
Merck) and n-butanol/ water/acetic acid (3/3/2 V/V/V) as mobile 
phase;
 — TLC on silica gel plates — modifications:
 silica gel TLC plates (Kieselgel 60 DC-Plastikfolien; 105748; 
Merck) and several compositions of mobile phase: n-propanol 
/ water / acetic acid: (4/3/1 V/V/V), (4/2/1 V/V/V), (4/1/1 V/V/V), 
etc.
 — TLC on silica gel plates and water as mobile phase [22].
Distribution of radioactivity on the developed and dried 
chromatographic strips/plates was analyzed using linear gamma 
Radio-TLC Scanner (BioScan) and by autoradiography using 
Cyclone Plus Storage Phosphor Scanner (Perkin Elmer).
In vivo studies
Biodistribution studies were performed in normal Wistar 
rats (male, weighing 190 ± 10 g) according to the procedure de-
scribed in Ph. Eur. monograph No. 0643 [16]. Briefly, ca. 12 MBq 
of the 99mTc- and 9-21 MBq of 188Re-labelled preparations, respec-
tively, in 0.2 mL volume were injected intravenously (i.v.) through 
the tail vein. Five rats were used per each tested preparation. The 
rats were sacrificed at 1 h post injection (p.i.) and the tissues and 
organs were excised, rinsed with saline, weighed and counted 
in a scintillation gamma counter supplied with an adapter for the 
whole-body measurement. Distribution of the activity in different 
organs was expressed as percentage of injected radioactivity 
dose per organ (%ID) and as percentage of injected dose per 
gram of tissue (%ID/g). 
All animal experiments were performed after approval by The 
IVth Local Animal Ethics Committee in Warsaw and were carried 
out in accordance with the principles of good laboratory practice.
Results and discussion
Table 1 shows the results of RCP determination of different 
DMSA preparations using selected TLC systems. In the chro-
matographic system recommended by the Ph. Eur. monograph 
for RCP testing of 99mTc-succimer [16], 99mTc(III)-DMSA complex 
remains at the application point, the same like most of the tech-
netium-99m radiopharmaceuticals, and an unbound 99mTc in the 
form of pertechnetate migrates with the solvent front. This method 
enables quantitative determination of technetium-99m in the form 
of pertechnetate only. Therefore, the biodistribution testing of the 
99mTc-DMSA in normal rats is required by the Ph. Eur. monograph 
to assure that the preparation is suitable for renal scanning.
Vanlić-Razumenić and Petrović [22] proposed quite smart 
method using silica gel plates and water as mobile phase for 
determination of the colloidal forms of 99mTc or 188Re in DMSA 
preparations. Our investigations confirmed that using this method 
the pertechnetate (perrhenate), as well as, the pentavalent and 
trivalent complexes of 99mTc and 188Re with DMSA migrate with the 
solvent front while colloidal forms are retained at the origin. Hence, 
the method can be recommended for investigation of the colloidal 
form of the radionuclide in DMSA preparations, although a small 
unspecific retention of radioactivity at the application point (ca. 
0.3%) should be taken into account (Table 1). 
The TLC method proposed by Westera et al. [21] utilizing 
silica gel coated plates and n-BuOH/H2O/acetic acid (3/3/2 
V/V/V) allows separation of the trivalent and pentavalent DMSA 
complexes (Figure 3A) in a chromatographic process lasting 2 h. 
This chromatographic system enables also detection of colloidal 
forms of 99mTc and/or 99mTc(III)-DMSA complex in 99mTc(V)-DMSA 
preparations and vice versa. A rather long time of chromatographic 
process (ca. 2 h) is a main disadvantage of the method. Therefore, 
in the present study we tested also some modifications using the 
same silica gel plates (Kieselgel 60 Plastikfolien, Merck) and vary-
ing compositions of the mobile phase. The n-butanol has been 
replaced by n-propanol as it is a solvent better soluble in water. 
Changes in the water and acetic acid contents were tested with 
regard to the separation power of the system, as well as the time 
needed to complete analysis (Figure 3B and 3C). 
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Modification of the chromatographic system by using silica 
gel plates and n-PrOH/H2O/AcOH (4/3/1 V/V/V) as mobile phase 
showed excellent resolution power for the DMSA complexes with 
188Re (Figure 3D). The system was a little bit faster (ca. 1 h 20 min 
vs. ca. 2 h) and revealed good separation ability with regard to 
differentiation between various radiochemical entities present 
in the DMSA preparations. It was clearly seen, especially for 
188Re-DMSA preparation obtained by the indirect method using Kit 
2 and intermediate 188Re(III)-EDTA complex, which always resulted 
in a mixture of radioactive entities, i.e.: 188Re(V)-DMSA, 188Re(V)-
EDTA/DMSA, 188Re(III)-EDTA, etc. 
Blower et al. [13] have proposed RP-HPLC method, which 
can separate anti, syn-endo and syn-exo stereoisomers (Fig. 2) 
of the pentavalent 99mTc- or 188Re-DMSA complexes. We also ex-
amined this HPLC method for investigations of radioactive DMSA 
complexes. However, in spite of observation of characteristic set 
of peaks corresponding to the stereoisomers, the radiochromato-
grams obtained did not provide complete information on all radio-
Table 1. Typical retardation factors (Rf) for radioactive entities in the DMSA preparations determined in different TLC systems
Preparations ITLC-SG;MEK 
(developing time ca. 
10 min )
SG60; H2O SG60; 
BuOH/ H2O/CH3COOH 
(3/3/2) 
(developing time ca. 2 h)
SG60; 
PrOH/H2O/CH3COOH 
(4/3/1) 
(developing time ca. 1 h 20 min)
Rf (% activity) Rf (% activity) Rf (% activity) Rf (% activity)
99mTc-pertechnetate/188Re-
perrhenate
0.9–1.0 (100%) 0.9–1.0 (99.7%) 0.8–0.9 (100%) 0.8–0.9 (100%)
99mTc/188Re-colloid 0.0 (100%) 0.0 (100%) 0.0 (100%) 0.0 (100%)
99mTc(V)-DMSA 0.0–0.1 (100%) 0.9–1.0 (99.7%) 0.6–0.7 (> 90%) 0.6 (> 97%)
99mTc(III)-DMSA 0.0–0.1 (100%) 0.9–1.0 (> 97%) 0.0–0.4 (56%)
0.5–0.6 (26%)
0.7 (17%)
0.0–0.4 (86%) 
0.5 (5%)
0.6 (9–10%)
188Re(V)-DMSA 
 — Kit No. 1
0.0–01 (100%) 0.9–1.0 (> 99.7%) 0.6–0.7 (100%) 0.6 (100%)
188Re(EDTA)DMSA 
 — Kit No. 2
– – 0.0 (22%) 
0.4 (40%)
0.6–0.7 (44%)
0.0 (17%) 
0.5 (28%) 
0.6 (38%)
Figure 3. The TLC autoradiograms of 99mTc- and 188Re-DMSA complexes, obtained using silicagel 60 plates developed in various mobile phases: A. 
n-BuOH/ H2O/AcOH (3/3/2 V/V/V) (the method published by Westera et al. [21]); B. n-PrOH/H2O/AcOH (4/1/1 V/V/V); C. n-PrOH/H2O/AcOH (4/3/1 
V/V/V); D. n-PrOH/H2O/AcOH (4/3/1 V/V/V)
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chemical forms present in the 99mTc- or 188Re-DMSA preparations. 
This was due to the fact that the trivalent complexes were strongly 
retained or precipitated on the chromatographic column, as in the 
case of the 99mTc-colloidal forms, and the calculation of radioactivity 
balance showed that usually not more than 10% of the injected 
99mTc(III)-DMSA was eluted from the column. Additionally, it is worth 
to note that a quantitative contribution of particular stereoisomers, 
as seen on the RP-HPLC radiochromatograms, does not have any 
practical utility since no significant differences in organ distribu-
tion and kinetics in-vivo were observed for the separated isomers, 
which would favour the use of purified stereo isomers over the 
isomeric mixture of 188Re(V)-DMSA [23]. 
The results of biodistribution of 99mTc(III)- and 99mTc(V)-DMSA 
in normal Wistar rats are presented in Table 2. As required by 
the specification given in the Ph. Eur. monograph [16], the 
trivalent complex accumulated mainly in kidneys (> 40 %ID) 
and showed low excretion with urine. Differently, 99mTc(V)-DMSA 
complex revealed high excretion with urine (>35 %ID 1h p.i.v.) 
and relatively high concentration in osseous tissue (ca. 2 %ID/g). 
Accumulation of this complex in kidneys was very low (ca. 2.5 
%ID). The biodistribution pattern of 188Re(V)-DMSA prepared 
from Kit 1, which usually enabled preparation of the complex of 
high radiochemical purity (93-98%), was almost identical to that 
of 99mTc(V)-DMSA. For 188Re preparation obtained using Kit 2, the 
biodistribution results indicated that the preparation contained the 
mixture of pentavalent and trivalent 188Re complexes. The quite 
high accumulation of radioactivity in kidneys (23 %ID) confirmed 
the presence of 188Re(III)-DMSA in this preparation, what was also 
determined by the TLC analysis performed using silica gel plate 
and n-propanol/water/acetic acid as developing system. 
Conclusions
In order to predict the in vivo efficacy of DMSA based ra-
diopharmaceuticals for diagnostic or therapeutic applications, 
not only the information on radiochemical impurities such as the 
pertechnetate/perrhenate and colloidal residues of radiometal 
is crucial but also on the tri- or pentavalent DMSA complexes, 
since the contribution of each of them influences the biodistribu-
tion of radiopharmaceutical. We have shown that a well-matched 
constituents and radiolabelling conditions enable preparation 
of pentavalent 99mTc/188Re-DMSA complexes of very high radio-
chemical purity (> 95%). To properly predict biological behaviour 
of the DMSA preparations, reliable analytical investigations are 
necessary before its clinical application. Among the tested chro-
matographic systems none can be considered alone as universal 
for determination of identity and radiochemical purity of DMSA 
complexes. Based on our study, for RCP testing of DMSA ra-
diopharmaceuticals we recommend TLC using SG60 coated 
plates and n-propanol, water and acetic acid in the developing 
solution, because this chromatographic system enables separa-
tion of the tri- and pentavalent DMSA complexes, as well as the 
impurities in the form of the pertechnetate or perrhenate ions. If 
combined with the TLC method for the determination of the col-
loidal residues [22], these two chromatographic systems will give 
comprehensive identification of all radiochemical entities, which 
may be present in 99mTc(188Re)-DMSA preparations. 
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